Effects of topical isoxsuprine ointment on imiquimod-induced psoriasiform skin inflammation in mice.
Clobetasol
Imiquimod
Interleukin
Isoxsuprine
Psoriasis
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
received:
22
02
2024
accepted:
02
08
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
8
8
2024
Statut:
aheadofprint
Résumé
This study assesses the potential positive impact of a 0.05% isoxsuprine ointment on psoriasiform skin inflammation generated by imiquimod in mouse models. Thirty-two male albino mice were allocated into four groups: the control group (which received topical emollients twice daily for 16 days), the induction group (which received imiquimod cream (5%) for 8 days, twice daily followed by petrolatum gel (15%) for another 8 days), and the other two groups, which received imiquimod cream (5%) for 8 days followed by either clobetasol ointment (0.05%) or isoxsuprine ointment (0.05%) twice daily for an additional 8 days. At the end of the experiment, mice were sacrificed by ethical standards, and levels of TNF-α, IL-6, IL-17A, IL-23, and VEGF were measured; PASI and Backer's score were examined, in addition to the histopathology of skin tissue. Each clobetasol and isoxsuprine group displayed a significant reduction in tissue homogenate levels of TNF-α, IL-6, IL-17A, IL-23, and VEGF, besides increments in IL-10 compared to the induction group. Some markers (IL-17A, IL23, and VEGF) showed no significant difference between clobetasol and the isoxsuprine group. In contrast, the other markers (TNF-α, IL6, and IL10) showed significant differences between clobetasol and isoxsuprine groups. Isoxsuprine ointment showed comparable efficacy to clobetasol ointment in treating imiquimod-induced psoriasiform skin inflammation in mice models, probably due to its possible effect of anti-inflammatory and immunomodulatory activities.
Identifiants
pubmed: 39115559
doi: 10.1007/s00210-024-03359-2
pii: 10.1007/s00210-024-03359-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ahmed NH, Kadhim Al-Zubaidy AA, Qasim BJ (2021) Effect of topical tadalafil gel in imiquimod-induced psoriasiform skin inflammation in mice. Indian J Forensic Med Toxicol 15:1572-1577
Al-juhaishi AMR, Al-Zubaidy AAK, Al-Mousawy JMM (2021) Effects of montelukast on imiquimod-induced model of psoriasis in mice. NVEO-Natural Volatiles & Essential Oils Journal| NVEO 8:3160–3171
Ali Z, Robert Zibert J, Dahiya P, Bachdal Johansen C, Grønlund Holm J, Ravn Jørgensen A-H, Manole I, Suru A, Egeberg A, Francis Thomsen S, Andersen AD (2023) Mild-to-moderate severity of psoriasis may be assessed remotely based on photographs and self-reported extent of skin involvement. JAAD Int 11:129–136. https://doi.org/10.1016/j.jdin.2023.02.004
doi: 10.1016/j.jdin.2023.02.004
pubmed: 37128265
pmcid: 10148150
Aronson JK (2016) Isoxsuprine. In: Aronson JK (ed) Meyler’s side effects of drugs (Sixteenth Edition). Elsevier, Oxford
Baek JO, Byamba D, Wu WH, Kim TG, Lee MG (2012) Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stress. Arch Dermatol Res 304:699–706. https://doi.org/10.1007/s00403-012-1272-y
doi: 10.1007/s00403-012-1272-y
pubmed: 22864965
Baker BS, Fry L (1992) The immunology of psoriasis. Br J Dermatol 126:1–9. https://doi.org/10.1111/j.1365-2133.1992.tb08394.x
doi: 10.1111/j.1365-2133.1992.tb08394.x
pubmed: 1536755
Baliwag J, Barnes DH, Johnston A (2015) Cytokines in psoriasis. Cytokine 73:342–350. https://doi.org/10.1016/j.cyto.2014.12.014
doi: 10.1016/j.cyto.2014.12.014
pubmed: 25585875
pmcid: 4437803
Baraka K, Abozahra RR, Badr E, Abdelhamid SM (2023) Study of some potential biomarkers in Egyptian hepatitis C virus patients in relation to liver disease progression and HCC. BMC Cancer 23:938. https://doi.org/10.1186/s12885-023-11420-1
doi: 10.1186/s12885-023-11420-1
pubmed: 37798688
pmcid: 10552374
Boehncke W-H, Brembilla NC (2018) Unmet needs in the field of psoriasis: pathogenesis and treatment. Clin Rev Allergy Immunol 55:295–311. https://doi.org/10.1007/s12016-017-8634-3
doi: 10.1007/s12016-017-8634-3
pubmed: 28780731
Brembilla NC, Boehncke W-H (2023) Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol 14. https://doi.org/10.3389/fimmu.2023.1186455
Bu J, Ding R, Zhou L, Chen X, Shen E (2022) Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol 13:880201. https://doi.org/10.3389/fimmu.2022.880201
doi: 10.3389/fimmu.2022.880201
pubmed: 35757712
pmcid: 9226890
Cardiff RD, Miller CH, Munn RJ (2014) Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc 2014:655–658. https://doi.org/10.1101/pdb.prot073411
doi: 10.1101/pdb.prot073411
pubmed: 24890205
Carvalho MdFPd, Pereira CSB, Fregnani JH, Ribeiro FdAQ (2015) Comparative histological study on wound healing on rat’s skin treated with Mitomycin C or Clobetasol propionate. Acta Cir Bras 30:593-7
Charan J, Kantharia ND (2013) How to calculate sample size in animal studies? J Pharmacol Pharmacother 4:303–306. https://doi.org/10.4103/0976-500x.119726
doi: 10.4103/0976-500x.119726
pubmed: 24250214
pmcid: 3826013
Chen Y, Zhang Q, Liu H, Lu C, Liang C-L, Qiu F, Han L, Dai Z (2018) Esculetin ameliorates psoriasis-like skin disease in mice by inducing CD4+Foxp3+ regulatory T cells. Front Immunol 9. https://doi.org/10.3389/fimmu.2018.02092
Ciccarelli M, Santulli G, Pascale V, Trimarco B, Iaccarino G (2013) Adrenergic receptors and metabolism: role in development of cardiovascular disease. Front Physiol 4:265. https://doi.org/10.3389/fphys.2013.00265
doi: 10.3389/fphys.2013.00265
pubmed: 24106479
pmcid: 3789271
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A (2021) Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 84:432–470. https://doi.org/10.1016/j.jaad.2020.07.087
doi: 10.1016/j.jaad.2020.07.087
pubmed: 32738429
Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39:175–191. https://doi.org/10.3758/bf03193146
doi: 10.3758/bf03193146
pubmed: 17695343
Festing MFW (2006) Design and statistical methods in studies using animal models of development. ILAR J 47:5–14. https://doi.org/10.1093/ilar.47.1.5
doi: 10.1093/ilar.47.1.5
pubmed: 16391426
Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A (2007) Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9:461–467. https://doi.org/10.1007/s11926-007-0075-1
doi: 10.1007/s11926-007-0075-1
pubmed: 18177599
pmcid: 2893221
Fragoulis GE, Siebert S, McInnes IB (2016) Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med 67:337–353. https://doi.org/10.1146/annurev-med-051914-021944
doi: 10.1146/annurev-med-051914-021944
pubmed: 26565676
Fredriksson T, Pettersson U (2009) Severe psoriasis – oral therapy with a new retinoid. Dermatologica 157:238–244. https://doi.org/10.1159/000250839
doi: 10.1159/000250839
Gnansekaran R, Mohammad C, Saini NK, Aggarwal V, Mishra S, Mehta SS, Satvantsinh BR, Prasanna MSH, Srikanth S, Gupta A (2022) Clobetasol propionate cream 0.025%: a topical therapeutic for dermatological disorders. Int J Res Med Sci, 10:1169–1175. https://doi.org/10.18203/2320-6012.ijrms20221021
Grän F, Kerstan A, Serfling E, Goebeler M, Muhammad K (2020) Current developments in the immunology of psoriasis. Yale J Biol Med 93:97–110
pubmed: 32226340
pmcid: 7087066
Hanania NA, Moore RH (2004) Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy 3:271–277. https://doi.org/10.2174/1568010043343598
doi: 10.2174/1568010043343598
pubmed: 15379595
Hao Y, Peng B, Che D, Zheng Y, Kong S, Liu R, Shi J, Han H, Wang J, Cao J, Zhang Y, Gao J, He L, Geng S (2020) Imiquimod-related dermatitis is mainly mediated by mast cell degranulation via Mas-related G-protein coupled receptor B2. Int Immunopharmacol 81:106258. https://doi.org/10.1016/j.intimp.2020.106258
doi: 10.1016/j.intimp.2020.106258
pubmed: 32044660
Higashihara T, Nishi H, Takemura K, Watanabe H, Maruyama T, Inagi R, Tanaka T, Nangaku M (2021) β2-adrenergic receptor agonist counteracts skeletal muscle atrophy and oxidative stress in uremic mice. Sci Rep 11:9130. https://doi.org/10.1038/s41598-021-88438-7
doi: 10.1038/s41598-021-88438-7
pubmed: 33911115
pmcid: 8080640
Hostrup M, Jacobson GA, Jessen S, Lemminger AK (2020) Anabolic and lipolytic actions of beta(2) -agonists in humans and antidoping challenges. Drug Test Anal 12:597–609. https://doi.org/10.1002/dta.2728
doi: 10.1002/dta.2728
pubmed: 31960603
Hostrup M, Onslev J (2022) The beta(2) -adrenergic receptor - a re-emerging target to combat obesity and induce leanness? J Physiol 600:1209–1227. https://doi.org/10.1113/jp281819
doi: 10.1113/jp281819
pubmed: 34676534
Hu R, Sou K, Takeoka S (2020) A rapid and highly sensitive biomarker detection platform based on a temperature-responsive liposome-linked immunosorbent assay. Sci Rep 10:18086. https://doi.org/10.1038/s41598-020-75011-x
doi: 10.1038/s41598-020-75011-x
pubmed: 33093468
pmcid: 7582967
Hu Y, Jiang L, Lei L, Luo L, Guo H, Zhou Y, Huang J, Chen J, Zeng Q (2022) Establishment and validation of psoriasis evaluation models. Fundam Res 2:166–176. https://doi.org/10.1016/j.fmre.2021.08.020
doi: 10.1016/j.fmre.2021.08.020
pubmed: 38933908
Indrayan A, Malhotra RK (2017) Medical biostatistics. Chapman and Hall/CRC
Jabeen M, Boisgard AS, Danoy A, El Kholti N, Salvi JP, Boulieu R, Fromy B, Verrier B, Lamrayah M (2020) Advanced characterization of imiquimod-induced psoriasis-like mouse model. Pharmaceutics 12. https://doi.org/10.3390/pharmaceutics12090789
Jyothi SL, Krishna KL, Ameena Shirin VK, Sankar R, Pramod K, Gangadharappa HV (2021) Drug delivery systems for the treatment of psoriasis: current status and prospects. J Drug Deliv Sci Technol 62:102364. https://doi.org/10.1016/j.jddst.2021.102364
doi: 10.1016/j.jddst.2021.102364
Kim WB, Jerome D, Yeung J (2017) Diagnosis and management of psoriasis. Can Fam Physician 63:278–285
pubmed: 28404701
pmcid: 5389757
Kimura M, Tarumoto Y, Nakane S, Otomo S (1986) Comparative toxicity study of hydrocortisone 17-butyrate 21-propionate (HBP) ointment and other topical corticosteroids in rats. Drugs Exp Clin Res 12:643–652
pubmed: 3757761
Lin Y-K, Yang S-H, Chen C-C, Kao H-C, Fang J-Y (2015) Using imiquimod-induced psoriasis-like skin as a model to measure the skin penetration of anti-psoriatic drugs. PLoS ONE 10:e0137890. https://doi.org/10.1371/journal.pone.0137890
doi: 10.1371/journal.pone.0137890
pubmed: 26355594
pmcid: 4565663
Lowes MA, Suárez-Fariñas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32:227–255. https://doi.org/10.1146/annurev-immunol-032713-120225
doi: 10.1146/annurev-immunol-032713-120225
pubmed: 24655295
pmcid: 4229247
Luo DQ, Wu HH, Zhao YK, Liu JH, Wang F (2016) Original research: different imiquimod creams resulting in differential effects for imiquimod-induced psoriatic mouse models. Exp Biol Med (Maywood) 241:1733–1738. https://doi.org/10.1177/1535370216647183
doi: 10.1177/1535370216647183
pubmed: 27190266
pmcid: 5027933
Luo Y, Tang H, Li H, Zhao R, Huang Q, Liu J (2019) Recent advances in the development of neuroprotective agents and therapeutic targets in the treatment of cerebral ischemia. Eur J Med Chem 162:132–146. https://doi.org/10.1016/j.ejmech.2018.11.014
doi: 10.1016/j.ejmech.2018.11.014
pubmed: 30445263
Manna MJ, Jalil MS, Jabur MS (2021) Topical isoxsuprine in experimentally induced hypertrophic scar in rabbits. J Popul Ther Clin Pharmacol 28:63–72. https://doi.org/10.47750/jptcp.2021.835
Marzo A, Zava D, Coa K, Dal Bo L, Ismaili S, Tavazzi S, Cantoni V (2009) Pharmacokinetics of isoxsuprine hydrochloride administered orally and intramuscularly to female healthy volunteers. Arzneimittelforschung 59:455–460. https://doi.org/10.1055/s-0031-1296425
doi: 10.1055/s-0031-1296425
pubmed: 19856793
Medina-Ruiz D, Erreguin-Luna B, Luna-Vázquez FJ, Romo-Mancillas A, Rojas-Molina A, Ibarra-Alvarado C (2019) Vasodilation elicited by isoxsuprine, identified by high-throughput virtual screening of compound libraries, involves activation of the NO/cGMP and H₂S/K(ATP) pathways and blockade of α₁-adrenoceptors and calcium channels. Molecules 24. https://doi.org/10.3390/molecules24050987
Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG (2021) Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb) 11:385–400. https://doi.org/10.1007/s13555-021-00483-2
doi: 10.1007/s13555-021-00483-2
pubmed: 33512665
Mohammed SS, Kadhim HM, Al-Sudani IM, Musatafa WW (2022) Anti-inflammatory effects of topically applied azilsartan in a mouse model of imiquimod-induced psoriasis. Int J Drug Deliv Technol 12:1249–1255
doi: 10.25258/ijddt.12.3.53
Motiejunaite J, Amar L, Vidal-Petiot E (2021) Adrenergic receptors and cardiovascular effects of catecholamines. Ann Endocrinol (Paris) 82:193–197. https://doi.org/10.1016/j.ando.2020.03.012
doi: 10.1016/j.ando.2020.03.012
pubmed: 32473788
Mustafa Thamer S, Q. Yahya M (2023) The effect of lenalidomide ointment on TNF-α tissue levels in mice with imiquimod-induced psoriasis the effect of lenalidomide ointment on TNF-α tissue levels in mice with imiquimod-induced psoriasis. J Fac Med Baghdad 64:252–260. https://doi.org/10.32007/jfacmedbagdad.6441959
O’Leary AP, Fox JM, Pullar CE (2015) Beta-adrenoceptor activation reduces both dermal microvascular endothelial cell migration via a cAMP-dependent mechanism and wound angiogenesis. J Cell Physiol 230:356–365. https://doi.org/10.1002/jcp.24716
doi: 10.1002/jcp.24716
pubmed: 24986762
Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guérin A, Ganguli A (2018) Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol 17:187–194
pubmed: 29462227
Patel N, Tollefson M (2019) Psoriasis. In: Hoeger P, Kinsler V, Yan A, Harper J, Oranje A, Bodemer C, Larralde M, Luk D, Mendiratta V, Purvis V (eds.) Harper's Textbook of Pediatric Dermatology. https://doi.org/10.1002/9781119142812.ch30
Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Hurst V, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H (2020) Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLOS Biol 18:e3000411. https://doi.org/10.1371/journal.pbio.3000411
Pierozan P, Jernerén F, Ransome Y, Karlsson O (2017) The choice of euthanasia method affects metabolic serum biomarkers. Basic Clin Pharmacol Toxicol 121:113–118. https://doi.org/10.1111/bcpt.12774
doi: 10.1111/bcpt.12774
pubmed: 28244216
pmcid: 6013688
Plagens-Rotman K, Przybylska R, Adamski Z, Czarnecka-Operacz M (2018) Skin and mucous membranes’ manifestations of dermatological diseases within the genital area in females. Postepy Dermatol Alergol 35:199–203. https://doi.org/10.5114/ada.2018.75243
doi: 10.5114/ada.2018.75243
pubmed: 29760622
pmcid: 5949551
Pukale SS, Sharma S, Dalela M, Singh AK, Mohanty S, Mittal A, Chitkara D (2020) Multi-component clobetasol-loaded monolithic lipid-polymer hybrid nanoparticles ameliorate imiquimod-induced psoriasis-like skin inflammation in Swiss albino mice. Acta Biomater 115:393–409. https://doi.org/10.1016/j.actbio.2020.08.020
doi: 10.1016/j.actbio.2020.08.020
pubmed: 32846238
Qu Y, Li D, Xiong H, Shi D (2023) Transcriptional regulation on effector T cells in the pathogenesis of psoriasis. Eur J Med Res 28:182. https://doi.org/10.1186/s40001-023-01144-0
doi: 10.1186/s40001-023-01144-0
pubmed: 37270497
pmcid: 10239166
Rapalli VK, Singhvi G, Dubey SK, Gupta G, Chellappan DK, Dua K (2018) Emerging landscape in psoriasis management: from topical application to targeting biomolecules. Biomed Pharmacother 106:707–713. https://doi.org/10.1016/j.biopha.2018.06.136
doi: 10.1016/j.biopha.2018.06.136
pubmed: 29990862
Rendon A, Schäkel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20. https://doi.org/10.3390/ijms20061475
Salman HR, Al-Zubaidy AA, Abbas AH, Zigam QA (2024) The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice. Naunyn Schmiedebergs Arch Pharmacol 397:599–616. https://doi.org/10.1007/s00210-023-02629-9
doi: 10.1007/s00210-023-02629-9
pubmed: 37490123
Shimo T, Takahara Y, Noguchi Y, Mukawa A, Kato H, Ito Y (1982) Comparative toxicity test of dexamethasone valerate (DV-17) and other steroid ointments in rats. J Toxicol Sci 7(Suppl 1):15–33. https://doi.org/10.2131/jts.7.supplementi_15
doi: 10.2131/jts.7.supplementi_15
pubmed: 7154134
Sidgiddi S, Naqvi SMH, Shenoy M, Balraj DN, Kothari J, Gupta S, Haq R, Mittal R, Mehta S, Mane A (2021) Efficacy and safety of novel formulation of clobetasol propionate 0.025% cream in Indian moderate-to-severe psoriasis patients: phase-2a, randomized 3-arm study. Dermatol Ther (Heidelb) 11:1717–1732. https://doi.org/10.1007/s13555-021-00591-z
doi: 10.1007/s13555-021-00591-z
pubmed: 34453262
Sivamani RK, Shi B, Griffiths E, Vu SM, Lev-Tov HA, Dahle S, Chigbrow M, La TD, Mashburn C, Peavy TR, Isseroff RR (2014) Acute wounding alters the beta2-adrenergic signaling and catecholamine synthetic pathways in keratinocytes. J Invest Dermatol 134:2258–2266. https://doi.org/10.1038/jid.2014.137
doi: 10.1038/jid.2014.137
pubmed: 24614156
Underwood W, Anthony R (2020) AVMA guidelines for the euthanasia of animals: 2020 edition. Retrieved on March, 2013, 2020-1
USP. The United States pharmacopeia and national formulary; USP 37-NF 32 (2014) US Pharmacopeial Convention Rockville, MD
van der Fits L, Mourits S, Voerman JS, Kant M, Boon L, Laman JD, Cornelissen F, Mus AM, Florencia E, Prens EP, Lubberts E (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182:5836–5845. https://doi.org/10.4049/jimmunol.0802999
doi: 10.4049/jimmunol.0802999
pubmed: 19380832
Varma SR, Sivaprakasam TO, Mishra A, Prabhu S, M R, P R (2017) Imiquimod-induced psoriasis-like inflammation in differentiated human keratinocytes: its evaluation using curcumin. Eur J Pharmacol 813:33-41. https://doi.org/10.1016/j.ejphar.2017.07.040
Wang J, Zhou Y, Zhang H, Hu L, Liu J, Wang L, Wang T, Zhang H, Cong L, Wang Q (2023) Pathogenesis of allergic diseases and implications for therapeutic interventions. Signal Transduct Target Ther 8:138. https://doi.org/10.1038/s41392-023-01344-4
doi: 10.1038/s41392-023-01344-4
pubmed: 36964157
pmcid: 10039055
Xanthopoulos A, Daskalopoulou I, Frountzi S, Papadimitriou E (2021) A systematic review on the role of adrenergic receptors in angiogenesis regulation in health and disease. Int J Transl Med 1:353–365
Xu R, Feng S, Ao Z, Chen Y, Su C, Feng X, Fu Q, Yang X (2022) Long-Acting β(2) Adrenergic receptor agonist ameliorates imiquimod-induced psoriasis-like skin lesion by regulating keratinocyte proliferation and apoptosis. Front Pharmacol 13:865715. https://doi.org/10.3389/fphar.2022.865715
doi: 10.3389/fphar.2022.865715
pubmed: 35795567
pmcid: 9250983